NEW YORK, NY / ACCESSWIRE / February 1, 2018 / U.S. markets rallied late Wednesday to close in the green, with the Dow Jones and S&P 500 posting their best monthly gain since March 2016. The Dow Jones Industrial Average gained 0.28 percent to close at 26,149.39, for a monthly gain of 5.79 percent, while the S&P 500 Index rose 0.05 percent to close at 2,823.81, for a monthly gain of 5.62 percent. The Nasdaq Composite Index increased 0.12 percent to close at 7,411.48, for a monthly gain of 7.36 percent. The Nasdaq's monthly rise was the most since October 2015. On Wednesday, the Federal Reserve stated that it expects inflation "up this year and to stabilize" around its 2 percent target. An interest rate hike is widely expected to happen at the next Fed meeting in March.
RDI Initiates Coverage on:
Incyte's stock moved 2.39% lower Wednesday, to close the day at $90.29. The stock recorded a trading volume of 1,404,592 shares, which was below its three months average volume of 1,661,827 shares. In the last year, Incyte's shares have traded in a range of 88.81 - 153.15. The stock is currently trading 41.04% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $95.47 is below its 200-day moving average of $111.60. Shares of Incyte have fallen roughly 4.67 percent in the past month.
Access RDI's Incyte Corporation Research Report at:
On Wednesday, shares of Intrexon recorded a trading volume of 1,695,868 shares, which was below the three months average volume of 1,953,285 shares. The stock ended the day 2.18% lower at 13.00. The share price has gained 26.71% from its 52 week low with a 52 week trading range of 10.26 - 26.99. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $13.06 is below its 200-day moving average of $16.74. Shares of Intrexon have gained roughly 12.85 percent in the past month.
Access RDI's Intrexon Corporation Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.